Loading...
Market
Best-selling liraglutide medication in Brazil in 2025?
3
Resolution / Starting Odds
Ozempic • 25%
Lirux • 25%
Olire • 25%
Other • 25%
Sales data from pharmaceutical companies and industry reports
Story
Anvisa Approves EMS Production of Liraglutide Medications Lirux and Olire, First Competitor to Ozempic, for Sale in 2025
Dec 24, 2024, 02:11 PM
The Brazilian Health Regulatory Agency (Anvisa) has approved the production of two liraglutide-based medications by the pharmaceutical company EMS. The drugs, named Lirux and Olire, are intended for the treatment of type 2 diabetes and obesity, respectively. This marks the introduction of the first national competitor to Ozempic, a medication widely used for similar purposes. The approval was officially published in the Diário Oficial on December 23, 2024, and the medications are expected to be available for commercial sale in 2025. In a separate development, Anvisa has prohibited a supplement that falsely claimed to cure diabetes, which had been linked to misleading information about the disease.
View original story
Similar markets
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Ozempic • 25%
Mounjaro • 25%
Wegovy • 25%
Other • 25%
Top 20 • 25%
Top 10 • 25%
Top 5 • 25%
Below Top 20 • 25%
Other • 25%
Saxenda • 25%
Zepbound • 25%
Wegovy • 25%
Top 3 in the sector • 25%
Top 5 in the sector • 25%
Outside top 5 • 25%
Leader in the sector • 25%
Somewhat positive • 25%
Negative • 25%
Highly positive • 25%
Neutral • 25%
Novo Nordisk 40-60% • 25%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
40% to 50% • 25%
Less than 30% • 25%
30% to 40% • 25%
More than 50% • 25%
Metabolic Liver Dysfunction • 25%
Other • 25%
Obstructive Sleep Apnea • 25%
Alzheimer's Disease • 25%